BioLattice

Revolutionizing Tissue Repair

Based based in United States, BioLattice works in medtech, founded in 2014.

Profile

BioLattice is on a mission to end corneal blindness. Only 1 in 70 patients who need cornea tissue get access to it. Globally 2 million per year suffer from corneal blindness while only 200,000 per year receive vision restoration through corneal transplants. Over 12 million worldwide are on a donor cornea tissue waiting list, and those with access to donor cornea face challenges including a 10% chance of implant failure within year 1. Even with immunosuppressant drops needed after surgery, the chances of rejection still rise to almost 50% by year 15 with the risk of going blind again. Our engineered cornea, CorneaClearTM, is a synthetic room temperature stable material that will restore AND correct vision. CorneaClearTM will disrupt the standard of care of donor cornea tissue usage in full thickness corneal transplants.

Within the medtech space, the company focuses on its core offering rather than a broad product line.

Its base of operations is United States.

The company is listed at the SOSV portfolio company stage of development.

The company reports a headcount in the 2-10 range.

Public records show total funding of about $1M.

Website: biolatticetech.com